Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  McWilliams Koeppen, Helen P ^a   Foster, James S ^a   Hackenbrack, Nicole ^a   Ramirez Alvarado, Marina ^b   Donohoe, Dallas ^c   Williams, Angela ^a   Macy, Sallie ^a   Wooliver, Craig ^a   Wortham, Dale ^a   Morrell Falvey, Jennifer ^d   Foster, Carmen M ^d   Kennel, Stephen J ^a   Wall, Jonathan S ^a  

^a UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TENNESSEE   (United States)

^d OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMYLOID; MONOMER; OXYGEN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE DEHYDROGENASE;

AMYLOIDOSIS; ARTICLE; CELL COUNT; CELL DEATH; CELL METABOLISM; CELL SURFACE; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVITY; HEART AMYLOIDOSIS; HEART CELL CULTURE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNALIZATION; OXYGEN CONSUMPTION; CARDIAC MUSCLE CELL; CELL LINE; CELL SURVIVAL; CHEMISTRY; CONFOCAL MICROSCOPY; ENZYMOLOGY; FLUORESCENCE MICROSCOPY; GENETICS; METABOLISM;

ADENOSINE TRIPHOSPHATE; AMYLOID; CELL LINE; CELL SURVIVAL; HUMANS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MYOCYTES, CARDIAC; NADPH DEHYDROGENASE; OXYGEN; REACTIVE OXYGEN SPECIES;

EID: 84947447926     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0137716     Document Type: Article

References (52)

1. Blancas-Mejia LM, Ramirez-Alvarado M. Systemic amyloidoses. Annual review of biochemistry. 2013; 82:745-74. Epub 2013/03/05. doi: 10.1146/annurev-biochem-072611-130030 PMID: 23451869; Pub Med Central PMCID: PMC4044913.
2. Merlini G, Seldin DC, Gertz MA. Amyloidosis: pathogenesis and new therapeutic options. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29(14):1924-33. Epub 2011/04/13. doi: 10.1200/JCO.2010.32.2271 PMID: 21483018; Pub Med Central PMCID: PMC3138545.
3. McLaughlin RW, De Stigter JK, Sikkink LA, Baden EM, Ramirez-Alvarado M. The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein. Protein science: a publication of the Protein Society. 2006; 15 (7):1710-22. Epub 2006/06/06. doi: 10.1110/ps.051997606 PMID: 16751605; Pub Med Central PMCID: PMC2242560.
4. Ramirez-Alvarado M, Merkel JS, Regan L. A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(16):8979-84. Epub 2000/07/26. doi: 10.1073/pnas.150091797 PMID: 10908649; Pub Med Central PMCID: PMC16807.
5. Hurle MR, Helms LR, Li L, Chan W, Wetzel R. A role for destabilizing amino acid replacements in lightchain amyloidosis. Proc Natl Acad Sci USA. 1994; 91:5446-50.
6. Kim Y, Wall JS, Meyer J, Murphy C, Randolph TW, Manning MC, et al. Thermodynamic modulation of light chain amyloid fibril formation. J Biol Chem. 2000; 275(3):1570-4. PMID: 10636846.
7. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, Solomon A. Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry. 1999; 38(42):14101-8. PMID: 10529258.
8. Wetzel R. Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem. 1997; 50:183-242.
9. Dispenzieri A, Gertz MA, Buadi F. What do I need to know about immunoglobulin light chain (AL) amyloidosis? Blood reviews. 2012; 26(4):137-54. Epub 2012/04/28. doi: 10.1016/j.blre.2012.03.001 PMID: 22537397.
10. Guan J, Mishra S, Falk RH, Liao R. Current perspectives on cardiac amyloidosis. American journal of physiology Heart and circulatory physiology. 2012; 302(3):H544-52. Epub 2011/11/08. doi: 10.1152/ajpheart.00815.2011 PMID: 22058156; Pub Med Central PMCID: PMC3353775.
11. Quarta CC, Kruger JL, Falk RH. Cardiac amyloidosis. Circulation. 2012; 126(12):e178-82. Epub 2012/09/19. doi: 10.1161/CIRCULATIONAHA.111.069195 PMID: 22988049.
12. Dubrey SW, Falk RH. Amyloid heart disease. British journal of hospital medicine. 2010; 71(2):76-82. Epub 2010/03/12. PMID: 20220694.
13. Dubrey SW, Hawkins PN, Falk RH. Amyloid diseases of the heart: assessment, diagnosis, and referral. Heart. 2011; 97(1):75-84. Epub 2010/12/15. doi: 10.1136/hrt.2009.190405 PMID: 21148582.
14. Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005; 112(13):2047-60. Epub 2005/09/28. doi: 10.1161/CIRCULATIONAHA.104.489187 PMID: 16186440.
15. Benilova I, Karran E, De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nature neuroscience. 2012; 15(3):349-57. Epub 2012/01/31. doi: 10.1038/nn.3028 PMID: 22286176.
16. Klein WL. Synaptotoxic amyloid-beta oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? Journal of Alzheimer's disease: JAD. 2013; 33 Suppl 1:S49-65. Epub 2012/07/13. doi: 10.3233/JAD-2012-129039 PMID: 22785404.
17. Haataja L, Gurlo T, Huang CJ, Butler PC. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocrine reviews. 2008; 29(3):303-16. Epub 2008/03/04. doi: 10.1210/er.2007-0037 PMID: 18314421; Pub Med Central PMCID: PMC2528855.
18. Zraika S, Hull RL, Verchere CB, Clark A, Potter KJ, Fraser PE, et al. Toxic oligomers and islet beta cell death: guilty by association or convicted by circumstantial evidence? Diabetologia. 2010; 53(6):1046-56. Epub 2010/02/26. doi: 10.1007/s00125-010-1671-6 PMID: 20182863; Pub Med Central PMCID: PMC3164873.
19. Sorgjerd K, Klingstedt T, Lindgren M, Kagedal K, Hammarstrom P. Prefibrillar transthyretin oligomers and cold stored native tetrameric transthyretin are cytotoxic in cell culture. Biochemical and biophysical research communications. 2008; 377(4):1072-8. Epub 2008/11/06. doi: 10.1016/j.bbrc.2008.10.121 PMID: 18983977.
20. Reixach N, Deechongkit S, Jiang X, Kelly JW, Buxbaum JN. Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(9):2817-22. Epub 2004/02/26. doi: 10.1073/pnas.0400062101 PMID: 14981241; Pub Med Central PMCID: PMC365703.
21. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood. 2006; 107(10):3854-8. Epub 2006/01/26. doi: 10.1182/blood-2005-11-4385 PMID: 16434487.
22. O'Hara CJ, Falk RH. The diagnosis and typing of cardiac amyloidosis. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis. 2003; 10(2):127-9. Epub 2003/09/11. PMID: 12964421.
23. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circulation research. 2004; 94(8):1008-10. Epub 2004/03/27. doi: 10.1161/01.RES.0000126569.75419.74 PMID: 15044325.
24. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(9):4188-93. Epub 2010/02/13. doi: 10.1073/pnas.0912263107 PMID: 20150510; Pub Med Central PMCID: PMC2840082.
25. Sikkink LA, Ramirez-Alvarado M. Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell death & disease. 2010; 1:e98. Epub 2010/01/01. doi: 10.1038/cddis.2010.75 PMID: 21368874; Pub Med Central PMCID: PMC3032327.
26. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001; 104- (14):1594-7. Epub 2001/10/03. PMID: 11581134.
27. Guan J, Mishra S, Shi J, Plovie E, Qiu Y, Cao X, et al. Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic research in cardiology. 2013; 108(5):378. Epub 2013/08/29. doi: 10.1007/s00395-013-0378-5 PMID: 23982491; Pub Med Central PMCID: PMC3914405.
28. Blancas-Mejia LM, Tellez LA, del Pozo-Yauner L, Becerril B, Sanchez-Ruiz JM, Fernandez-Velasco DA. Thermodynamic and kinetic characterization of a germ line human lambda6 light-chain protein: the relation between unfolding and fibrillogenesis. Journal of molecular biology. 2009; 386(4):1153-66. Epub 2009/01/22. doi: 10.1016/j.jmb.2008.12.069 PMID: 19154739.
29. Gonzalez-Andrade M, Becerril-Lujan B, Sanchez-Lopez R, Cecena-Alvarez H, Perez-Carreon JI, Ortiz E, et al. Mutational and genetic determinants of lambda6 light chain amyloidogenesis. The FEBS journal. 2013; 280(23):6173-83. Epub 2013/10/11. doi: 10.1111/febs.12538 PMID: 24107228.
30. Wall JS, Gupta V, Wilkerson M, Schell M, Loris R, Adams P, et al. Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins. J Mol Recognit. 2004; 17(4):323-31. PMID: 15227639.
31. Davidson MM, Nesti C, Palenzuela L, Walker WF, Hernandez E, Protas L, et al. Novel cell lines derived from adult human ventricular cardiomyocytes. Journal of molecular and cellular cardiology. 2005; 39- (1):133-47. Epub 2005/05/26. doi: 10.1016/j.yjmcc.2005.03.003 PMID: 15913645.
32. Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N. Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochemical and biophysical research communications. 2011; 410(4):707-13. Epub 2011/05/12. doi: 10.1016/j.bbrc.2011.04.133 PMID: 21557933; Pub Med Central PMCID: PMC3145458.
33. Wall J, Murphy CL, Solomon A. In vitro immunoglobulin light chain fibrillogenesis. Methods Enzymol. 1999; 309:204-17. PMID: 10507026.
34. Kueng W, Silber E, Eppenberger U. Quantification of cells cultured on 96-well plates. Analytical biochemistry. 1989; 182(1):16-9. Epub 1989/10/01. PMID: 2604040.
35. Voigt S, Philipp S, Davarnia P, Winoto-Morbach S, Roder C, Arenz C, et al. TRAIL-induced programmed necrosis as a novel approach to eliminate tumor cells. BMC cancer. 2014; 14:74. Epub 2014/02/11. doi: 10.1186/1471-2407-14-74 PMID: 24507727; Pub Med Central PMCID: PMC3927850.
36. Wall JS, Richey T, Stuckey A, Donnell R, Macy S, Martin EB, et al. In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides. Proc Natl Acad Sci U S A. 2011; 108(34):E586-94. PMID: 21807994. doi: 10.1073/pnas.1103247108
37. Rosenkranz AR, Schmaldienst S, Stuhlmeier KM, Chen W, Knapp W, Zlabinger GJ. A microplate assay for the detection of oxidative products using 2′,7′-dichlorofluorescin-diacetate. Journal of immunological methods. 1992; 156(1):39-45. Epub 1992/11/25. PMID: 1431161.
38. Wang G, Gong Y, Burczynski FJ, Hasinoff BB. Cell lysis with dimethyl sulphoxide produces stable homogeneous solutions in the dichlorofluorescein oxidative stress assay. Free radical research. 2008; 42(5):435-41. Epub 2008/05/20. doi: 10.1080/10715760802074462 PMID: 18484276.
39. Levinson RT, Olatoye OO, Randles EG, Howell KG, Di Costanzo AC, Ramirez-Alvarado M. Role of mutations in the cellular internalization of amyloidogenic light chains into cardiomyocytes. Scientific reports. 2013; 3:1278. Epub 2013/02/19. doi: 10.1038/srep01278 PMID: 23417147; Pub Med Central PMCID: PMC3575045.
40. Ancsin JB. Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis. 2003; 10(2):67-79. Epub 2003/09/11. PMID: 12964414.
41. Migrino RQ, Truran S, Gutterman DD, Franco DA, Bright M, Schlundt B, et al. Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. American journal of physiology Heart and circulatory physiology. 2011; 301(6):H2305-12. Epub 2011/10/04. doi: 10.1152/ajpheart.00503.2011 PMID: 21963839; Pub Med Central PMCID: PMC3233808.
42. Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, et al. p38 kinase is activated in the Alzheimer's disease brain. Journal of neurochemistry. 1999; 72(5):2053-8. Epub 1999/04/27. PMID: 10217284.
43. Migrino RQ, Hari P, Gutterman DD, Bright M, Truran S, Schlundt B, et al. Systemic and microvascular oxidative stress induced by light chain amyloidosis. International journal of cardiology. 2010; 145- (1):67-8. Epub 2009/05/19. doi: 10.1016/j.ijcard.2009.04.044 PMID: 19446898; Pub Med Central PMCID: PMC2974792.
44. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. American journal of physiology Cell physiology. 2007; 292(1): C125-36. Epub 2006/09/15. doi: 10.1152/ajpcell.00247.2006 PMID: 16971499.
45. Jin Y, McEwen ML, Nottingham SA, Maragos WF, Dragicevic NB, Sullivan PG, et al. The mitochondrial uncoupling agent 2,4-dinitrophenol improves mitochondrial function, attenuates oxidative damage, and increases white matter sparing in the contused spinal cord. Journal of neurotrauma. 2004; 21- (10):1396-404. Epub 2005/01/28. PMID: 15672630.
46. Okuda M, Lee HC, Kumar C, Chance B. Comparison of the effect of a mitochondrial uncoupler, 2,4-dinitrophenol and adrenaline on oxygen radical production in the isolated perfused rat liver. Acta physiologica Scandinavica. 1992; 145(2):159-68. Epub 1992/06/01. doi: 10.1111/j.1748-1716.1992. tb09351.x PMID: 1322018.
47. Patel SP, Sullivan PG, Pandya JD, Rabchevsky AG. Differential effects of the mitochondrial uncoupling agent, 2,4-dinitrophenol, or the nitroxide antioxidant, Tempol, on synaptic or nonsynaptic mitochondria after spinal cord injury. Journal of neuroscience research. 2009; 87(1):130-40. Epub 2008/08/19. doi: 10.1002/jnr.21814 PMID: 18709657.
48. Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnology annual review. 2005; 11:127-52. Epub 2005/10/12. doi: 10.1016/S1387-2656(05)11004-7 PMID: 16216776.
49. Keeling J, Herrera GA. An in vitro model of light chain deposition disease. Kidney international. 2009; 75(6):634-45. Epub 2008/10/17. doi: 10.1038/ki.2008.504 PMID: 18923384.
50. Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA. Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Laboratory investigation; a journal of technical methods and pathology. 2004; 84(4):440-51. Epub 2004/03/03. doi: 10.1038/labinvest.3700069 PMID: 14990980.
51. Wall JS, Kennel SJ, Williams A, Richey T, Stuckey A, Huang Y, et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PloS one. 2012; 7(12):e52686. Epub 2013/01/10. doi: 10.1371/journal.pone.0052686 PMID: 23300743; Pub Med Central PMCID: PMC3530443.
52. Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT, et al. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010; 116(13):2241-4. PMID: 20522711. doi: 10.1182/blood-2010-03-273797